Infection can be **catastrophic**

Don't take chances, take action.
Protect your patients from the inside out with Ethicon's unique combination of wound closure devices that provides watertight closure and protection against bacteria at every layer as shown in vitro.[1-5]



STRATAFIX™ Knotless Tissue Control Devices

- Secure, watertight closure of the deeper layers[1,2]
- The only barbed device with **Plus Antibacterial Technology**,* shown in vitro to inhibit bacterial colonization of the device for 7 days or more[3,4]

DERMABOND® PRINEO® Skin Closure System

- **Watertight**, flexible microbial barrier for the skin—in vitro studies have shown that DERMABOND PRINEO System acts as a barrier to microbial penetration[5,6]
- **Proven 99% effective** through 72 hours in vitro against bacteria most commonly associated with surgical site infection, including *Pseudomonas aeruginosa*, *Escherichia coli*, *Enterococcus faecium*, *Staphylococcus aureus*, and *Staphylococcus epidermidis*[5]
- Demonstrated in vitro to **kill 99.9% of bacteria** (MRSA, MRSE, and *E. coli*) **on direct contact**[7†]

ETHICON
PART OF THE Johnson & Johnson FAMILY OF COMPANIES
Shaping the future of surgery

*Refers only to STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device, STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device, and STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Device.
†Clinical significance unknown

Many factors can challenge the outcome of your procedures.
Bacteria shouldn't be one of them.

From deep tissue layers to the skin, Ethicon products help protect against bacterial infiltration.[1-5]

STRATAFIX™ Knotless Tissue Control Devices

STRATAFIX Knotless Tissue Control Devices with Plus Antibacterial Technology (triclosan) are proven in vivo to **kill bacteria on the suture known to be associated with SSIs**,[4,8,9*†] and provide the **wound-holding strength** of interrupted suturing, with greater security and efficiency than continuous suturing.[10-19]

STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device provides excellent holding strength and can be used in **high-tension areas, such as fascia**.[10,20-24]

DERMABOND® PRINEO® Skin Closure System

DERMABOND PRINEO System combines the proven strength, flexibility, and **antimicrobial protection** of DERMABOND ADVANCED® Topical Skin Adhesive with the added support and security of a self-adhering mesh to further facilitate both wound-edge approximation and an optimal healing environment.[6,25-29]

Shown to provide statistically significant **greater skin-holding strength** than skin staples or subcuticular suture.[30‡]

Meta-analysis demonstrates 28% reduction in SSI risk with the use of triclosan-coated sutures[31*†]

- 21 RCTs, 6,462 patients, 95% CI: (14, 40%), *P*<0.001
- All triclosan-coated sutures in these RCTs were Ethicon Plus Antibacterial Sutures
- Meta-regression analyses demonstrated that the effect of triclosan-coated sutures in reducing the risk of SSI does not vary by CDC wound classification‡ or suture type*

Based on evidence such as this, triclosan-coated sutures are recommended by several leading health authorities, including:

Centers for Disease Control and Prevention (CDC)
Consider the use of triclosan-coated sutures for the prevention of SSI[32§]

World Health Organization (WHO)
The panel suggests the use of triclosan-coated sutures for the purpose of reducing the risk of SSI, independent of the type of surgery[33§]

National Health & Medical Research Council of Australia
Using antimicrobial-coated sutures (included on the ARTG e.g triclosan coated sutures) can help to reduce SSI rates.[34§]

§CDC, WHO, NHMRC guidelines on reducing the risk of surgical site infections are general to triclosan-coated sutures and are not specific to any one brand.

Plus Antibacterial Sutures from Ethicon are the only commercially available triclosan-coated sutures in Australia and New Zealand.

*Refers only to STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device, STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device, and STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Device.
†In an animal model
‡In an ex-vivo study, more load in N was required to create a 3±1 mm gap between skin edges approximated with DERMABOND PRINEO System, than with subcuticular 4-0 MONOCRYL Suture or PROXIMATE® Ethicon Endo-Surgery skin staples (p=0.00).

*21 RCTs, 6,462 patients, 95% CI: (14, 40%), *P*<0.001
†All triclosan-coated sutures in these RCTs were Ethicon Plus Antibacterial Sutures (MONOCRYL® Plus Antibacterial (poliglecaprone 25) Suture, Coated VICRYL® Plus Antibacterial (polyglactin 910) Suture and PDS® Plus Antibacterial (polydioxanone) Suture)
‡Clean wounds 10 RCT, 2,842 patients, 95% CI: (11-43%). *P*=0.003; non-clean wounds 14 RCT, 3,620 patients, 95% CI: (7-42%).

Help protect your patients from the threat of infection with the unique combination of wound closure devices, **only from Ethicon**

For further information, please contact your local Ethicon representative, or contact customer service on 1800 252 194 (Australia) or 0800 803 988 (New Zealand)

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

References: 1. Nett M, Avelar R, Sheehan M, Cushner F. Water-tight knee arthrotomy closure: comparison of a novel single bidirectional barbed self-retaining running suture versus conventional interrupted sutures. *J Knee Surg.* 2011;24:55-59. **2.** Shikanov S, Wille M, Large M, Lifshitz DA, Zorn KC, Shalhav AL, Eggener SE. Knotless closure of the collecting system and renal parenchyma with a novel barbed suture during laparoscopic porcine partial nephrectomy. *J Endurology.* 2009;23:1157-1160. **3.** Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of MONOCRYL plus antibacterial suture (Poligelcaprone 25 with triclosan). *Surg Infect (Larchmt).* 2007;8(2):201-207. **4.** Ming X, Rothenburger S, Nichols MM. In vivo and in vitro antibacterial efficacy of PDS plus (polidioxanone with triclosan) suture. *Surg Infect (Larchmt).* 2008;9(4):451-457. **5.** Su W. Study report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape. 06TR071. December 4, 2006. Ethicon, Inc. **6.** DERMABOND® PRINEO® Skin Closure System, Instructions for Use. Ethicon, Inc. **7.** Bhende S. In-vitro study to evaluate the ability of DERMABOND™ PRINEO™ Skin Closure System to kill bacteria on contact. June 22, 2012. Ethicon, Inc. **8.** Storch ML, Rothenburger S, Jacinto G. Experimental efficacy study of coated VICRYL plus antibacterial suture in guinea pigs challenged with staphylococcus aureus. *Surg Infect (Larchmt).* 2004;5(3):281-288. **9.** Ming X, Rothenburger S, Nichols MM, Rothenburger S. In vivo antibacterial efficacy of MONOCRYL plus antibacterial (poliglecaprone 25 with triclosan). *Surg Infect (Larchmt).* 2007; 8(2):1-5. **10.** 100326296: Time zero tissue holding - Competitive claims comparisons for STRATAFIX Knotless Tissue Control Devices vs various products. 2015. Ethicon, Inc. **11.** Ethicon study AST-2012-0331. Tissue gapping under tension of porcine cadaveric skin incisions closed with Stratafix Spiral in comparison to Monocryl in both interrupted and continuous stitching patterns. Approved on August 24, 2012. Ethicon, Inc. **12.** AST-2013-0056 Performance testing of STRATAFIX Symmetric PDS size 2-0 suture device for tissue holding strength with multiple incision defects to measure gapping. Ethicon, Inc. **13.** Ethicon performance evaluation memo AST-2012-0510. Performance testing of STRATAFIX Symmetric size 2-0 suture device for tissue holding strength with an incision defect to measure gapping. December 3, 2012. Ethicon, Inc. **14.** Vakil JJ, O'Reilly MP, Sutter EG, Mears SC, Belko SM, Khanuja HS. Knee arthrotomy repair with a continuous barbed suture: a biomechanical study. *J Arthroplasty.* 2011;26(5):710-713. **15.** Eickmann T, Quane E. Total knee arthroplasty closure with barbed sutures. *J Knee Surg.* 2010;23(3):163-167. **16.** Levine BR, Ting N, Della Valle CJ. Use of a barbed suture in the closure of hip and knee arthroplasty wounds. *Orthopedics.* 2011;34(9):e473-e475. **17.** Moran ME, Marsh C, Perrotti M. Bidirectional-barbed sutured knotless running anastomosis v classic Van Velthoven suturing in a model system. *J Endourol.* 2007;21(10):1175-1178. **18.** Einarsson JI, Chavan NR, Suzuki Y, Jonsdottir G, Vellinga TT, Greenberg JA. Use of bidirectional barbed suture in laparoscopic myomectomy: evaluation of perioperative outcomes, safety, and efficacy. *J Minim Invasive Gynecol.* 2011;18(1):92-95. **19.** Warner JP, Gutowski KA. Abdominoplasty with progressive tension closure using a barbed suture technique. *Aesthet Surg J.* 2009;29(3):221-225. **20.** Ethicon study AST-2011-0210. Study to evaluate the tissue holding performance at time zero of DOLFIN PDS Plus barbed suture sizes 1 and 2-0 vs dyed PDS II Plus suture sizes 1 and 2-0 in a continuous stitch pattern—Project DOLFIN 11822, version 1. Approved on July 15, 2011. Ethicon, Inc. **21.** Ethicon study AST-2011-0341. Performance testing of DOLFIN PDS Plus size 3-0 suture—tissue holding 10 cm incision. Approved on August 22, 2011. Ethicon, Inc. **22.** Ethicon study PSE 09-0204, project number 11822. Exploratory histological and biomechanical evaluation of DOLFIN following closure of the ventral abdominal wall in a porcine model at 7±1 days. Approved on July 7, 2010. Ethicon, Inc. **23.** Ethicon study PSE 10-0012, project number 11822. Model development: histological and biomechanical evaluation of 3-0 DOLFIN barbed suture prototypes, 3-0 Quill suture, and 3-0 V-loc suture at 7±1 days following closure of the ventral abdominal wall in a rabbit model. Approved on August 8, 2011. Ethicon, Inc. **24.** Performance Testing of STRATAFIX SYMMETRIC PDS Plus size 0 & 1 Devices – Initiation strength in porcine tissue. AST-2013-0603. Ethicon, Inc. **25.** Keplinger S. Protocol investigation of the comparison of PRINEO with conventional wound closure techniques. 07PD048. Ethicon, Inc. **26.** Multi-centre study to show equivalence of DERMABOND PROTAPE to INTRADERMAL SUTURES for skin closure of full thickness surgical incisions associated with breast procedures. 07CS003. July 9, 2010. Ethicon, Inc. **27.** Multi-centre study to show equivalence of DERMABOND PROTAPE to INTRADERMAL SUTURES for skin closure of full thickness surgical incisions. 06CS005, June 10, 2010. **28.** Shapiro AJ, Dinsmore RC, North JH, Tensile strength of wound closure with cyanoacrylate glue. *Am Surg.* 2001;67:1113-1115. **29.** Kannon GA, Garrett AB. Moist wound healing with occlusive dressings. *Dermatol Surg.* 1995;21:583-590. **30.** Kumar A. Study to compare the tissue holding strength of PRINEO™ skin closure system with conventional wound closure techniques. AST-2012-0290. October 11, 2012. Ethicon, Inc. **31.** de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical site infection. *Brit J Surg.* 2017;104(2):e118-e133. **32.** Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. *JAMA Surg.* 2017;152(8):784-791. **33.** WHO Global Guidelines for the Prevention of Surgical Site Infection, 2016. **34.** Australian Guidelines for the Prevention and Control of Infection in Healthcare, Canberra: National Health and Medical Research Council (2019).

ETHICON
PART OF THE Johnson & Johnson FAMILY OF COMPANIES

Shaping the future of surgery

AUSTRALIA: Johnson & Johnson Medical Pty. Ltd.
1-5 Khartoum Rd, North Ryde NSW 2113
NEW ZEALAND: Johnson & Johnson (NZ) Ltd.
507 Mt Wellington Hwy, Mt Wellington, Auckland 1060

120623-190812 August 2019